9th Adriatic and 6th Croatian Congress on Pharmacoeconomics and Outcomes Research: Solutions for improving access to healthcare innovation in CEE region

THURSDAY (11 April 2019)

14:00 Welcome address by Congress President, Dinko Vitezic
14:10 Welcome address by Congress President, Igor Francetic
14:15 Welcome address by EACPT Past President, Tabassome Simon
14:20 Welcome address by Croatian Ministry of Health

KEY NOTE SPEECH
14:30 Eduard Vrdoljak: Economic evaluation of the Croatian National Cancer Control Plan

15:00 Discussion
15:10 Coffee break

National oncology strategies and programs - how patient centric are they? Example of Croatian Cancer Control Plan

Chairmen: Igor Francetic, Ingrid Belac Lovasic

15:30 Viktorija Erdeljic-Turk: The future of access to innovative medicines in cancer therapy in Croatia
15:50 Sinisa Varga: ‘Members of European Parliament against cancer’ - concept and objectives
16:10 Slobodanka Bolanca: Is affordability the only limitation to cancer treatments in CEE?

Round table discussion:
National oncology strategies and programs - how patient centric are they? Example of Croatian Cancer Control Plan
Moderator: Sinisa Varga

17:45 Closure of Day 1
18:00 Welcome reception

FRIDAY (12 April 2019)

Selected pharmacoeconomic and outcomes research studies - what can we learn from them?

Chairmen: Dinko Vitezic, Iva Kraljickovic

09:00 Aleksandar Knezevic: Cost comparison of stroke prevention in atrial fibrillation: warfarine vs new oral anticoagulants
09:20 Vanesa Benkovic: The cost of stroke in Croatia
09:40 Tereza Saric: Diabetes care in Croatia - clinical and economic consequences
10:00 Marta Kucan: Cost effectiveness of antihypertensive drugs - balance of clinical and pharmacoeconomic outcomes
10:20 Sinisa Varga (key note speech): Can We improve Healthcare decisions making for better patients outcomes in emergecy departments
10:50 Discussion

11:00 Coffee break

Fairness and equity in dealing with affordability challenges for new health technologies - any solution on a horizon?

Chairmen: Tea Strbad, Sinisa Varga

11:20 Jurij Furst: The systemic payback scheme
11:40 Livio Garattini: Dutch guidelines for economic evaluation: ‘from good to better’ in theory but further away from pharmaceuticals in practice?
12:00 Anze Droljc: The key to successful digital transformation
12:10 Stefano Lucherini: Modeling the budget impact and health outcomes of the anti PD-1/PD-L1 class in cancer care in Slovenia
12:40 Neda Vitezic: An Innovative Approach to Measuring Public Health Prevention Outcomes
12:50 Discussion

13:00 Lunch

Fairness and equity in dealing with affordability challenges for new health technologies - any solution on a horizon? - cont.

Chairmen: Robert Likic, Neda Vitezic

14:00 Slobodan Jankovic: Simple method for adjusting results of pharmacoeconomic studies from country to country using Bayesian statistics
14:20 Petra Dosenovic Bonca: Indirect versus direct economic impacts of ill health: insights from Slovenia
14:40 Barbara Stegel: Pharmaceutical spending trends in Slovenia
15:00 Faris Gavrankapetanovic: Essential lists in F/BIH - equity or equality
15:20 Tanja Novakovic: Solving the Big Data challenge of Medical Scientific Literature
15:40 Discussion

15:50 Coffee break

Pricing & Reimbursement Reform in Croatia - Expected Outcomes?

(this session will be held in Croatian language)

Chairmen: Dinko Vitezic, Viktorija Erdeljic-Turk

16:10 Tea Strbad: Current situation in pricing and reimbursement in Croatia
16:30 Sani Pogorilic: Future access to breakthrough technologies in Croatia
16:50 Tonci Buble: Generic medicines in Croatia: dilemmas for future
Round table discussion:

17:10 Pricing & Reimbursement Reform in Croatia - Expected Outcomes
Moderator: Dinko Vitezic

18:00 Roundtable Conclusion and Closure of Day 2

Poster session

Chairmen: Igor Francetic, Slobodan Jenkovic

18:00
18:05
18:10
18:15
18:20
18:25
18:30
Arijana Turcin, Robert Likic:
Deni Rkman, Kristijan Dominik Rudez, Igor Radanovic, Mijo Babic, Robert Likic, Iveta Mercep:
Kristian Dominik Rudez, Deni Rikman, Igor Radanovic, Tina Dusek, Sinisa Cikic, Darko Kastelan, Robert Likic:
Eric Nham, Kristian Dominik Rudez, Deni Rikman, Igor Radanovic, Igor Milovcic, Mato Primorac, Robert Likic:
Igor Radanovic, Deni Rikman, Kristian Dominik Rudez, Robert Likic:
Kristian Dominik Rudez, Deni Rikman, Igor Radanovic, Igor Milovcic, Mato Primorac, Robert Likic:
Igor Radanovic, Deni Rikman, Kristian Dominik Rudez, Robert Likic:
Marko Boskovic, Robert Likic:

18:30 Potential for savings through better control of overutilization of proton pump inhibitors

20:30 Congress dinner

SATURDAY (13 April 2019)

Importance of patients’ informed engagement in healthcare policy decisions

Chairmen: Natalija Petkovic Podjaversek, Bertalan Nemeth

09:00 Ivett Jakab: Patient centricity in health care
09:20 Luka Vencina: Archetypes of patients’ involvement in healthcare decision making in CEE
09:40 Marcela Omahen: Patient support programme: value for patients and payer
10:00 Livio Garattini: Patient empowerment in Europe: is no further research needed?
10:20 Ines Petoczajak: Clinical studies - is it worth it?
10:40 Discussion
10:50 Coffee break

Selected pharmacoeconomic and outcomes research studies - what can we learn from them?

Chairmen: Aleksandar Knezevic, Mirjana Huic
11:10 Robert Likic: Are fixed dose drug combinations pharmacoeconomically sound?
11:30 Krzysztof Landa: How to accelerate uptake of innovative drugs in prioritized medical fields - case study on schizophrenia
11:50 Zoltan Kalo: How to evaluate programs targeting the management of chronic multimorbid patients
12:10 Iva Kraljivic: Price and cost-effectiveness of new antibiotics
12:30 Stevie Acevski: Pharmacoeconomic aspect on antibiotic consumption in Macedonia in 2016
12:50 Discussion
13:00 Lunch

Access to orphan drugs: how to reconcile available funding and patients’ health needs?

Chairmen: Robert Likic, Carmen Kostrencic
14:00 Bruno Sepodes: Marketing Authorization and Patient Access to Orphan Medicinal Products: Creating Bridges over Troubled Waters
14:30 Zoltan Kalo: Challenges of funding orphan drugs in CEE
15:00 Dinko Vitezic: Orphan drugs: drug pricing vs incentives
15:30 Discussion
15:40 Coffee break

New frontiers and paradigmes in health technology assessment in Europe

Chairmen: Jurij Furst, Ivett Jakab
16:00 Mirjana Huic: Joint HTA work in EU: Current status and the future
16:20 Pero Draganic: Early Dialogue and a HTA/Payer’s perspective in a CEE
16:40 Bertalan Nemeth: Transferability of HTA: present and future trends from the CEE perspective

17:00 Round table discussion: Current and future ‘HTA / reimbursement assessment’ challenges in EU, and CEE
Moderator: Bertalan Nemeth

17:55 Roundtable Conclusion
**Congress Closing and Farewell**

18:00 Closing address by Congress President, Dinko Vitezic
18:10 Closing address by Congress President, Igor Francetic

**SUNDAY (14 April 2018)**

Open Joint Post Congress Meeting of Collaborative Associations - ISPOR, HDKFiT, INIFEZ, UZEFI

10:00 HDKFiT, INIFEZ: Feedback from the 9th Adriatic and 6th Croatian Congress on Pharmacoeconomics and Outcomes Research
10:30 HDKFiT, INIFEZ: Proposal for topics and committees for the 10th Adriatic Congress on Pharmacoeconomics and Outcomes Research
11:00 ALL: Possible joint regional research activities

12:30 Lunch and departures